Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Cancer Cell|May 30, 2017
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS LymphomaMichail S Lionakis, Kieron Dunleavy, Mark Roschewski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2020
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)Keith T Flaherty, Robert J Gray, Alice P Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2020
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt LymphomaMark Roschewski, Kieron Dunleavy, Jeremy S Abramson, et al.
Nature Medicine|June 15, 2023
The NCI-MATCH trial: lessons for precision oncologyPeter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
Blood|May 31, 2024
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCLMitchell R Smith, Opeyemi A Jegede, Peter Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2023
The New NCI Precision Medicine TrialsLyndsay N Harris, Charles D Blanke, Harry P Erba, et al.
The New England Journal of Medicine|December 4, 2018
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLJennifer A Woyach, Amy S Ruppert, Nyla A Heerema, et al.
Frontiers in Immunology|September 20, 2021
Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 TrialPolina Shindiapina, Maciej Pietrzak, Michal Seweryn, et al.
Blood|January 12, 2024
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLLJennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell LymphomaJacob D Soumerai, Andrew D Zelenetz, Craig H Moskowitz, et al.
Pageof 11